Acrylamides as potassium channel openers

Bibliography

• ROSSITER BE, SWINGLE NM: Asymmetric conjugate addition. Chem. Rev. (1992) 92(5):771-806.
   Web of Science ®Google Scholar
• LU X, LIN S: Pd(II)-bipyridine catalyzed conjugate addition of arylboronic acid to α, β-unsaturated carbonyl compounds. J. Org. Chem. (2005) 70(23):9651-9653.
   PubMed Web of Science ®Google Scholar
• HAYASHI T, YAMASAKI K: Rhodium-catalyzed asymmetric 1,4-addition and its related asymmetric reactions. Chem. Rev. (2003) 103(8):2829-2844.
   PubMed Web of Science ®Google Scholar
• NAKANE M, KOLASA T, CHANG R et al.: Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator. J. Pharmacol. Sci. (2006) 102(2):231-238.
   Google Scholar
• CHIDA N, HIRASAWA Y, OHKAWA T et al.: Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor. Eur. J. Pharmacol. (2005) 509(1):71-76.
   Google Scholar
• QI S, XU D, MA A et al.: Effect of a novel inducible nitric oxide synthase inhibitor, FR260330, in prevention of renal ischemia/reperfusion injury in vervet monkeys. Transplantation (2006) 81(4):627-631.
   PubMed Web of Science ®Google Scholar
• GREENSPAN PD, FUJIMOTO RA, MARSHALL PJ et al.: Carboxy-substituted cinnamides: a novel series of potent, orally active LTB4 receptor antagonists. J. Med. Chem. (1999) 42(1):164-172.
   Google Scholar
• KIMURA N, FUKUI H, TAKAGAKI H, YONEMOCHI E, TERADA K: Characterization of polymorphs of a novel quinolinone derivative, TA-270 (4-hydroxy-1-methyl-3-octyloxy-7-sinapinoylamino-2(1H)-quinolinone). Chem. Pharm. Bull. (2001) 49(10):1321-1325.
   PubMed Web of Science ®Google Scholar
• ISHIWARA M, AOKI Y, TAKAGAKI H, UI M, OKAJIMA F: TA-270 [4-hydroxy-1-methyl-3-octyloxy7-sinapinoylamino-2(1H)-quinolinone], an anti-asthmatic agent, inhibits leukotriene production induced by IgE receptor stimulation in RBL-2H3 cells. J. Pharmacol. Exp. Ther. (2003) 307(2):583-588.
   PubMedGoogle Scholar
• AOKI Y, ISHIWARA M, KODA A, TAKAGAKI H: Inhibitory effect of a novel quinolinone derivative, TA-270, on asthmatic inflammatory responses in sensitized guinea pigs. Eur. J. Pharmacol. (2000) 409(3):325-330.
   Google Scholar
• METCALFE DD, BARAM D, MEKORI YA: Mast cells. Physiol. Rev. (1997) 77(4):1033-1079.
   PubMed Web of Science ®Google Scholar
• LIU G, LINK JT, PEI Z et al.: Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead. J. Med. Chem. (2000) 43(21):4025-4040.
   PubMed Web of Science ®Google Scholar
• CHEN L, GUI C, LUO X et al.: Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J. Virol. (2005) 79(11):7095-7103.
   PubMed Web of Science ®Google Scholar
• AZUMA H, BANNO K, YOSHIMURA T: Pharmacological properties of N-(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′), a new anti-atopic agent. Br. J. Pharmacol. (1976) 58(4):483-488.
   PubMed Web of Science ®Google Scholar
• KODA A, NAGAI H, WATANABE S, YANAGIHARA Y, SAKAMOTO K: Inhibition of hypersensitivity reactions by a new drug, N(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′). J. Allergy Clin. Immunol. (1976) 57(5):396-407.
   PubMed Web of Science ®Google Scholar
• SELNICK HG, LIVERTON NJ, BALDWIN JJ et al.: Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide. J. Med. Chem. (1997) 40(24):3865-3868.
   PubMed Web of Science ®Google Scholar
• MUNEMORI M, YAMAOKA K, YUSUF I et al.: Effect of N-feruloyl tyramine (an analogue of tyramine) on inwardly rectifying potassium channel in frog ventricular myocytes. Hiroshima J. Med. Sci. (1996) 45(1):31-35.
   Google Scholar
• YUSUF I, YAMAOKA K, OTSUKA H, YAMASAKI K, SEYAMA I: Block of sodium channels by tyramine and its analogue (N-feruloyl tyramine) in frog ventricular myocytes. Jpn. J. Physiol. (1992) 42(2):179-191.
   Google Scholar
• SHIEH CC, COGHLAN M, SULLIVAN JP, GOPALAKRISHNAN M: Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol. Rev. (2000) 52(4):557-594.
   PubMed Web of Science ®Google Scholar
• LAWSON K, MCKAY NG: Modulation of potassium channels as a therapeutic approach. Curr. Pharm. Des. (2006) 12(4):459-470.
   PubMed Web of Science ®Google Scholar
• GARCIA ML, KACZOROWSKI GJ: Potassium channels as targets for therapeutic intervention. Sci. STKE (2005) 2005(302):46.
   Google Scholar
• SALKOFF L, BUTLER A, FERREIRA G, SANTI C, WEI A: High-conductance potassium channels of the SLO family. Nat. Rev. (2006) 7(12):921-931.
   Google Scholar
• WEIGER TM, HERMANN A, LEVITAN IB: Modulation of calcium-activated potassium channels. J. Comp. Physiol. (2002) 188(2):79-87.
   Google Scholar
• NARDI A, CALDERONE V, CHERICONI S, MORELLI I: Natural modulators of large-conductance calcium-activated potassium channels. Planta Medica (2003) 69(10):885-892.
   PubMedGoogle Scholar
• NARDI A, CALDERONE, V, OLESEN S-P: Potassium channel openers: the case of BK channel activators. Lett. Drug Design Discov. (2006) 3:210-218.
   Google Scholar
• BENTZEN BH, NARDI A, CALLOE K et al.: The small molecule NS11021 is a potent and specific activator of Ca2+-activated big conductance K+ channels. Mol. Pharmacol. (2007) (In Press).
   Google Scholar
• CHENEY JA, WEISSER JD, BAREYRE FM et al.: The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. J. Cereb. Blood Flow Metab. (2001) 21(4):396-403.
   PubMed Web of Science ®Google Scholar
• PERSIANI S, D'AMATO M, MAKOVEC F et al.: Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. Biopharm. Drug Dispos. (2001) 22(2):73-81.
   PubMedGoogle Scholar
• ISHIBASHI S, IKEDA U, IHARA T, SHIMADA K: Tranilast inhibits contraction and Ca2+ movement of porcine coronary arteries. Atherosclerosis (1997) 130(1-2):113-119.
   Google Scholar
• MALMGREN A, ANDERSSON KE, SJOGREN C, ANDERSSON PO: Effects of pinacidil and cromakalim (BRL 34915) on bladder function in rats with detrusor instability. J. Urol. (1989) 142(4):1134-1138.
   PubMed Web of Science ®Google Scholar
• ARGENTIERI TM, BUTERA JA: An overview of potassium channel activators for the treatment of overactive bladder: a survey of new structures 2000 – 2005. Expert Opin. Ther. Patents (2006) 16(5):573-585.
   Web of Science ®Google Scholar
• BUTERA JA, ANTANE SA, HIRTH B et al.: Synthesis and potassium channel opening activity of substituted 10H-benzo[4,5]furo[3,2-b]indole-and 5,10-dihydro-indeno[1,2-b]indole-1-carboxylic acids. Bioorg. Med. Chem. Lett. (2001) 11(16):2093-2097.
   PubMed Web of Science ®Google Scholar
• GUTMAN GA, CHANDY KG, ADELMAN JP et al.: International union of pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol. Rev. (2003) 55(4):583-586.
   PubMed Web of Science ®Google Scholar
• WANG HS, PAN Z, SHI W et al.: KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science (1998) 282(5395):1890-1893.
   PubMed Web of Science ®Google Scholar
• SCHROEDER BC, HECHENBERGER M, WEINREICH F, KUBISCH C, JENTSCH TJ: KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J. Biol. Chem. (2000) 275(31):24089-24095.
   PubMed Web of Science ®Google Scholar
• LERCHE C, SCHERER CR, SEEBOHM G et al.: Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity. J. Biol. Chem. (2000) 275(29):22395-22400.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN HB, FROKJAER-JENSEN C, JENSEN CS et al.: Requirement of subunit co-assembly and ankyrin-G for M-channel localization at the axon initial segment. J. Cell Sci. (2007) 120(Part 6):953-963.
   Google Scholar
• JENTSCH TJ: Neuronal KCNQ potassium channels: physiology and role in disease. Nat. Rev. (2000) 1(1):21-30.
   Google Scholar
• DALBY-BROWN W, HANSEN HH, KORSGAARD MP, MIRZA N, OLESEN SP: K(v)7 channels: function, pharmacology and channel modulators. Curr. Top. Med. Chem. (2006) 6(10):999-1023.
   PubMedGoogle Scholar
• MAIN MJ, CRYAN JE, DUPERE JR et al.: Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol. (2000) 58(2):253-262.
   PubMed Web of Science ®Google Scholar
• WICKENDEN AD, YU W, ZOU A, JEGLA T, WAGONER PK: Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol. Pharmacol. (2000) 58(3):591-600.
   PubMed Web of Science ®Google Scholar
• TATULIAN L, DELMAS P, ABOGADIE FC, BROWN DA: Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J. Neurosci. (2001) 21(15):5535-5545.
   PubMed Web of Science ®Google Scholar
• WICKENDEN AD, ZOU A, WAGONER PK, JEGLA T: Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br. J. Pharmacol. (2001) 132(2):381-384.
   PubMed Web of Science ®Google Scholar
• PORTER RJ, NOHRIA V, RUNDFELDT C: Retigabine. Neurotherapeutics (2007) 4(1):149-154.
   PubMed Web of Science ®Google Scholar
• WU YJ, DWORETZKY SI: Recent developments on KCNQ potassium channel openers. Curr. Med. Chem. (2005) 12(4):453-460.
   PubMedGoogle Scholar
• WU YJ, BOISSARD CG, GRECO C et al.: (S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]-3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. J. Med. Chem. (2003) 46(15):3197-3200.
   PubMed Web of Science ®Google Scholar
• BENTZEN BH, SCHMITT N, CALLOE K et al.: The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology (2006) 51(6):1068-1077.
   PubMedGoogle Scholar
• SCHENZER A, FRIEDRICH T, PUSH M et al.: Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsivant retigabine. J. Neurosci. (2005) 25(20):5051-5060.
   PubMed Web of Science ®Google Scholar
• WUTTKE TV, SEEBOHM G, BAIL S et al.: The new anticonvulsivant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol. Pharmacol. (2005) 67(4):1009-1017.
   PubMed Web of Science ®Google Scholar
• WU YJ, DAVIS CD, DWORETZKY S et al.: Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3-morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. J. Med. Chem. (2003) 46(15):3778-3781.
   PubMed Web of Science ®Google Scholar
• WU YJ, SUN LQ, HE H et al.: Synthesis and KCNQ2 opener activity of N-(1-benzo[1,3]dioxol-5-yl-ethyl, N-[1-(2,3-dihydro-benzofuran-5-yl)-ethyl, and N-[1-(2,3-dihydro-1H-indol-5-yl)-ethyl acrylamides. Bioorg. Med. Chem. Lett. (2004) 14(17):4533-4537.
   PubMedGoogle Scholar